<DOC>
	<DOCNO>NCT00004877</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness BMS-214662 treating patient advance solid tumor .</brief_summary>
	<brief_title>BMS-214662 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose , dose limit toxicity , recommend phase II dose , safety BMS-214662 patient advance solid tumor . II . Determine pharmacokinetics BMS-214662 patient . III . Assess absolute oral bioavailability BMS-214662 use capsule single intravenous dose patient . IV . Determine preliminary evidence antitumor activity BMS-214662 patient . OUTLINE : This dose escalation study . Patients receive BMS-214662 IV 1 hour day -7 , follow oral BMS-214662 daily day 0-14 course 1 . Beginning course 2 , patient receive oral BMS-214662 twice daily 14 day . Treatment continue every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BMS-214662 maximum tolerate dose ( MTD ) determine . The MTD define dose few 2 6 patient experience dose limit toxicity . Patients follow every 4 week toxicity resolve . PROJECTED ACCRUAL : A total 30-40 patient accrue study within 12-18 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor refractory standard therapy effective therapy exist No active brain metastasis include evidence cerebral edema CT MRI scan , progression prior image study , requirement steroid , clinical symptom PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL ALT AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine le 1.5 time ULN Cardiovascular : No uncontrolled significant cardiac disease No myocardial infarction within past 6 month No congestive heart failure ( without therapy ) No history atrial ventricular arrhythmia No history second third degree heart block No prolong QTc interval electrocardiogram Pulmonary : No uncontrolled significant pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious uncontrolled medical disorder active infection No dementia alter mental status No prior concurrent gastrointestinal disease within past 6 month No history malabsorption No impaired oral ingestion ( e.g. , patient feed tube ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy ( except replacement hormone therapy ) Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy great 25 % bone marrow No concurrent radiotherapy Surgery : No prior surgery would impact absorption BMS214662 Other : At least 4 week since prior investigational agent No concurrent experimental anticancer medication No prior CYP3A4 substrate within 1 week , , least 1 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>